Navigation Links
ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells

ATHENS, Ga., March 23 /PRNewswire/ -- ArunA Biomedical, Inc., announced today an agreement with Neuromics, Inc. of Edina, MN, giving Neuromics the right to non-exclusively market and sell the ArunA hN2(TM) Human Neural Cells and Neural Culture Medium to support applications in neurological research.

(Logo: )

ArunA has an exclusive worldwide license to develop and commercialize neural cells derived from human embryonic stem cells (hESC), and hN2 is a second generation product from this technology. These cells offer a consistent population of normal human neural cells that the neural research and pharmaceutical market highly desires.

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research, and we are pleased to have Neuromics as a distribution partner," said David Ray, Chief Executive Officer of ArunA Biomedical.

"Neuromics growth is catalyzed by offering the unique products and expertise our customers require for research success through strategic alliances with companies like ArunA Biomedical. This relationship represents a growth opportunity for us. Their hN2(TM) cells fill a stated research need of the Neuroscience Community and we look forward to our customers having these cells and the related new discoveries they will help generate," said Pete Shuster, CEO and Owner of Neuromics.

Founded in 2003, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and neuroscience research.

Founded in 2003, Neuromics is a privately held Bio-regents Company focusing on providing research ready and proven products and methods expertise to Neuroscience, Diabetes/Obesity, Immunology and Researchers.

This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.

SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
5. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)... 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a ... conditions, will present at two upcoming investor conferences. Aytu ... real-time virtual conference, to be held December 3, 2015, ... be held December 2 nd & 3 rd ... and streamed live via webcast. Josh Disbrow ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):